Wednesday, July 1, 2026

OXMIQ Raises $35 Million to Scale OxCore™ Architecture


 CAMPBELL, Calif. - 

(BUSINESS WIRE) -- OXMIQ Labs Inc., a unified GPU and AI architecture company founded by Raja Koduri, today closed its $35 million Series A financing, bringing the company’s total capital raised to $60 million. The funding will scale OxCore™, OXMIQ’s licensable GPU architecture that allows semiconductor companies and AI system builders to build custom AI silicon without a full chip program. The round was co-led by Fundomo and Samsung Catalyst Fund, with participation from MediaTek, AM Intelligence Labs, Pegatron Venture Capital, CDIB-TEN, Darwin Ventures, and Morgan Creek Digital, among other financial and strategic investors. OXMIQ’s expertise spans the full AI stack, from renewable power and data center infrastructure to silicon IP, electron-to-token machines (ETMs™), along with the software that runs AI factories and agents.


One Core, Three Engines


Token demand is outpacing the world’s ability to build infrastructure to serve it. OXMIQ was founded to re-architect the GPU stack from Atoms to Agents™, building the silicon IP, configurable systems and software platform that enable semiconductor companies and AI infrastructure builders to drive down the cost of intelligence at every layer of the stack.


At the center of the architecture is OxCore™, a scalable, licensable GPU core that integrates three distinct compute engines: a CUDA®-compatible GPU engine, a tensor processing engine, and an orchestration engine (CPU) responsible for coordinating workloads and agents across the system. OxCore tightly couples compute functionality that is typically split across three chips, and was purpose-built for near-memory compute, minimizing data movement to enhance compute and energy efficiency of AI workloads. OxCore was designed for scalability and the architecture scales efficiently from single-core AI deployments to large-scale datacenter configurations. OxCore is running on FPGA today, with live demonstrations available.


OxQuilt™, OXMIQ’s chiplet integration architecture, combines heterogeneous compute chiplets and memory in a single package. Most AI silicon designs are locked to a specific foundry and memory type. OxQuilt instead adapts to any supply chain, with configuration tools that let customers design across logic process nodes, memory types, interconnect standards, and advanced packaging options. By making high-performance AI compute licensable and configurable, OXMIQ lets any design team build custom AI silicon packages without needing cost-prohibitive full chip programs. The architecture is also designed to incorporate emerging interconnect technologies such as silicon photonics as they reach production readiness.


OXMIQ pairs the hardware with a software stack spanning OxCapsule™ for high-level orchestration to low-level kernel optimization. OxPython™ runs existing CUDA® and PyTorch® code on OxCore without code changes, giving developers full portability across hardware. This stack supports emerging silicon architectures for optimized inference at scale and delivers day-zero support for new models. OxPython has been validated on third-party platforms with live demos available.


OXMIQ’s IP-first model is built for capital efficiency. By focusing on new architecture IP rather than full SoC development, the company generates revenue from customer engagements while preserving capital for building the stack.


“We are very excited to co-lead OXMIQ’s financing round and back Raja Koduri and the strong team at OXMIQ,” said David (Dede) Goldschmidt, SVP & Managing Director, Head of the Samsung Catalyst Fund. “OXMIQ’s novel AI core and software platform enable heterogeneous compute for efficient, custom inference solutions serving large-scale agentic workloads.”


“Raja has built silicon at every layer of the stack, and he knows exactly where the constraints sit. Most compute IP makes the customer bend their memory, packaging, and foundry around the chip. OXMIQ does the opposite, and that flips a cost center into leverage. We backed this team because they will define how AI compute gets built this decade,” said Rajeev Surati, Partner at Fundomo.


An Expanding Team


OXMIQ has strengthened its board and advisory ranks with two additions that bring decades of silicon pedigree. Jim Keller, CEO of Tenstorrent and among the most influential chip architects in the industry, joins the board of directors alongside existing board member Dr. Ker Zhang. Dr. Valluri (Bob) Rao, a renowned Fellow who retired from Intel’s process technology group, joins as an advisor. Together, they deepen OXMIQ’s leadership as the company moves from architecture to customer integration.


“I am excited to join the OXMIQ board. Raja and this team are creating an open GPU architecture, a much-needed step toward removing the artificial boundaries around AI innovation. As the industry concentrates around a few incumbents, this is more important than ever. OXMIQ’s open, configurable foundation, which developers can build on and own, is exactly where compute should be heading,” said Jim Keller, CEO of Tenstorrent and OXMIQ board member.


Raja Koduri, OXMIQ founder and CEO, added: “A licensable core with an open architecture means design teams everywhere can build the custom AI silicon their work needs. Today, state-of-the-art AI reaches most people through a handful of channels, and the cost of the compute underneath is the reason. Bring that cost down, and you widen who gets to build with it. I believe AI is a force for good when it is a tool everyone can pick up and use, not just the few who can afford to build with it. Closing this round with investors who own the supply chain tells us we can get there.”


Get Involved


OXMIQ is working with semiconductor companies, neoclouds, AI system builders, and physical AI/robotics companies ready to own their compute roadmap. For licensing and partnership inquiries, contact licensing@oxmiq.ai.


Investors


The round was co-led by Fundomo, a New York venture firm focused on frontier compute infrastructure, and Samsung Catalyst Fund, Samsung Electronics’ evergreen multi-stage venture capital fund that invests in deep tech AI infrastructure. MediaTek, a seed investor and one of the world’s leading fabless semiconductor companies, is reinvesting.


Lawrence Loh, SVP of MediaTek, said, “MediaTek is actively powering today’s advanced AI capabilities from the edge to the cloud. Our investment in OXMIQ underscores this push and combines our AI ambitions with their highly flexible GPU architecture. We see this investment as a way to continue unlocking unprecedented on-device AI performance across all technology platforms.”


AM Intelligence Labs, part of the AM Green Group; a global leader in clean energy generation and scaled energy storage systems, global green hydrogen molecule market, and building AI infrastructure & token delivery factories; joins this round as an investor. The move extends the collaboration behind the 5GW AI factory initiative, including a 3GW renewable-powered AI compute platform, that AMI is building in India. CDIB-TEN is a joint fund between CDIB Capital, a leading Asian PE/VC firm expanding its asset management business through a strong regional presence anchored by over 65 years of investment heritage in Taiwan, and TEN Capital Corporation is a prestigious fund management company that is deeply wired into the semiconductor ecosystem in Taiwan and North America. Pegatron Venture Capital, the investment arm of one of the world's largest ODMs and system integrators, adds manufacturing and systems depth to carry chiplet AI accelerator designs from architecture to deployment. Morgan Creek Digital, an investor focused on AI and digital infrastructure, joins the round on the thesis that compute capacity and architecture choice will define the AI economy this decade. Darwin Venture Management, a Taipei-based venture firm investing across the Taiwan-Silicon Valley technology corridor, brings cross-border conviction that mirrors OXMIQ's own design and supply chain footprint. Intel Capital rounds out the group as a strategic IP partner, adding to OXMIQ's design and engineering depth.


About OXMIQ Labs


OXMIQ Labs is a GPU and AI architecture company with expertise spanning every layer of the AI stack, from renewable energy and data center infrastructure to silicon IP, electron-to-token machines, and cloud software for AI factories and agents. OXMIQ develops licensable compute IP and adaptive AI infrastructure software. The OXMIQ stack, OxCore™, OxQuilt™, OxPython™ and OxCapsule™, enables semiconductor companies, neoclouds, and AI system builders to develop and deploy custom AI compute across the full spectrum of AI applications. The company’s mission is to re-architect the GPU stack: from Atoms to Agents™, making high-performance AI compute available, affordable, and within reach of design teams and builders who need it. Founded by Raja Koduri, OXMIQ is headquartered in Campbell, California, with a development site in Hyderabad, India. Learn more at oxmiq.ai.


Trademark Acknowledgments


CUDA® is a trademark or registered trademark of NVIDIA Corporation in the U.S. and other countries. PyTorch is a trademark of the Linux Foundation. All other product names, trademarks and registered trademarks are the property of their respective owners and are used for identification purposes only.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260701241910/en/



Permalink

https://www.aetoswire.com/en/news/0107202656032


Contacts

Media Contact:

press@oxmiq.ai

NIQ Completes Acquisition of Flywheel’s China and Southeast Asia eCommerce Data & Insights Business, Expanding Digital Commerce Intelligence Capabilities

CHICAGO - Wednesday, 01. July 2026 AETOSWire  


(BUSINESS WIRE) -- NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced that it has completed the acquisition of Flywheel’s China and Southeast Asia eCommerce Data & Insights business. The acquired business operates in China under the YiMian (“一面”) brand and is a leading provider of eCommerce, social commerce, and digital shelf solutions.


The acquisition expands NIQ’s capabilities across China and Southeast Asia and strengthens its ability to measure and understand consumer behavior across retail, eCommerce, social commerce, and digital environments — advancing NIQ’s mission to deliver The Full View™, the most complete understanding of consumer behavior across online and offline channels. It also enhances NIQ’s data and analytics foundation by expanding access to rich digital commerce signals that support the development of more advanced analytics and AI-powered solutions.


By bringing together NIQ’s global intelligence, analytics, and retail measurement capabilities with the acquired business’ rich digital commerce data and expertise, NIQ will offer clients a more connected view of performance across marketplaces, social commerce, and the digital shelf. This will help clients improve visibility into pricing, assortment, availability, content quality, and competitive positioning, while making faster, more informed commercial decisions.


A key benefit of the acquisition is the introduction of Digital Shelf capabilities in China, enabling NIQ to deliver more consistent and comprehensive eCommerce insights across global and regional markets.


“Flywheel brings deep expertise in digital commerce, social commerce, and digital shelf measurement across China and Southeast Asia, along with a talented team that complements NIQ’s global scale,” said Rachel White, APAC Regional President of NIQ. “With the transaction now complete, we are excited to move forward together and help clients navigate today’s increasingly complex digital commerce landscape with richer insights and stronger decision support.”


“Joining forces with NIQ marks an exciting new chapter for our business and, most importantly, for our clients,” said Will Lv, General Manager, Flywheel. “Our expertise in digital commerce intelligence across China and Southeast Asia, combined with NIQ's global reach and analytics capabilities, creates a stronger platform for helping clients navigate complexity, move faster, and unlock growth.”


The acquired business supports more than 100 global and regional clients across China and Southeast Asia, reflecting its strong market position and trusted client relationships.


About NIQ


NielsenIQ (NYSE: NIQ) is a leading consumer intelligence company, delivering the most complete and trusted understanding of consumer buying behavior and revealing new pathways to growth. By combining an unmatched global data footprint and granular consumer and retail measurement with decades of AI modeling expertise, NIQ builds decision systems that help companies turn complex data into confident action.


With operations in more than 90 countries, NIQ covers approximately 82% of the world’s population and more than $7.4 trillion in global consumer spend. Through cloud-based platforms, advanced analytics and AI-driven insights, NIQ delivers The Full View™—helping brands and retailers understand what consumers buy, why they buy it, and what to do next.


For more information, please visit www.niq.com.


About YIMIAN


YIMIAN is a leading AI-powered commerce intelligence company that transforms digital commerce data into actionable business insights. Leveraging advanced AI and large-scale data from e-commerce and social media platforms, we help brands make informed decisions across strategy, innovation, marketing, sales, and digital commerce operations.


Trusted by leading companies in personal care, beauty, food and beverage, automotive, household products, consumer electronics, healthcare, and pet care, YIMIAN provides real-time market intelligence, consumer insights, competitive benchmarking, and performance tracking to accelerate growth in dynamic local markets.


Learn more at YIMIAN Official Website


#NIQ-IR


© 2026 Nielsen Consumer LLC. All Rights Reserved.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260701249579/en/



Permalink

https://www.aetoswire.com/en/news/0107202656030


Contacts

Media Contact: media.relations@nielseniq.com

IFF Launches SENSORA™, an Innovative Pro-Fragrance Technology Platform


 NEW YORK -

A light-activated fragrance experience enhancer, starting with liquid detergents


(BUSINESS WIRE)--IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients and health and biosciences — today announced the launch of SENSORA™, its advanced patent-pending pro-fragrance technology designed to transform how scent is experienced across home, fabric and personal care applications. Developed to meet the rising demand for a longer-lasting and more sophisticated scent experience, SENSORA™ delivers an evolving olfactive profile with sustained release, extending enjoyment well beyond first use.


“With SENSORA™, we are advancing fragrance performance into a new territory — one where scent continues to reveal itself in real life, long after the first moment of use,” said Ana Paula Mendonça, president of IFF Scent. “By combining pro-fragrance science with our deep expertise in fragrance design, we are creating more enduring, more meaningful experiences that bring consumers joy.”


Where pro-fragrance science meets fragrance experience enhancement


A pro-fragrance is a delivery system designed for the controlled release of scent. At the core of SENSORA™ is an innovative pro-fragrance mechanism engineered to unlock complex olfactive dimensions over time. This activation is triggered by light — both indoor and outdoor — enabling a controlled, phased release of scent from storage through wear.


SENSORA™ is designed to:


Sustain fragrance presence well beyond washing and into use

Reveal new olfactive facets over time, enhancing richness and sophistication

Extend scent perception for days — up to 20 days after activation

First application: fabric care


Today, IFF introduces Floral Fusion under the SENSORA™ platform — its first light-activated pro-fragrance specifically designed for liquid detergents — as part of its fragrance experience enhancer portfolio. It delivers a long-lasting, evolving scent experience, releasing refined floral notes on dry fabrics, enriching the fragrance experience beyond the original scent signature.


“SENSORA™ gives our customers a powerful new way to differentiate in laundry care, a category where consumers increasingly expect fragrance to deliver both lasting impact and elevated sensorial pleasure,” said Jan Bechtel, senior vice president of consumer fragrance for IFF Scent. “Starting with liquid detergents, this breakthrough offering creates new opportunities to build memorable product experiences, strengthen brand preference and respond to evolving consumer expectations.”


Meeting a clear consumer shift


An IFF global usage and attitudes survey conducted in 17 countries in 2026 found that consumers are increasingly seeking benefits that go beyond freshness to deliver lasting impact and sensorial pleasure:


More than one-third expect laundry fragrance to last longer

Nearly one in four want scent to remain noticeable for at least four days

SENSORA™ responds directly to these expectations, delivering premium scent performance designed for real-life conditions.


A scalable platform for future innovation


Part of IFF’s SCENT+™ innovation pillar and grounded in its Science of Performance, SENSORA™ integrates seamlessly into fragrance compositions, giving perfumers precise control to design bespoke performance profiles.


“SENSORA™ represents a step-change in how we design fragrance performance,” said Mohammed Ashour, vice president of innovation for IFF Scent. “Its light-activated pro-fragrance mechanism gives perfumers a new level of control to orchestrate how scent evolves, revealing new olfactive facets over time while providing a scalable platform for innovation across applications and categories.”


Welcome to IFF


At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.


© 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260629247253/en/



Permalink

https://aetoswire.com/en/news/54562579


Contacts

 

Contact: Judith Gross, VP, Communications & Branding

Department: Scent

Email: scentmediarequest@iff.com


 

Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS

 IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade


(BUSINESS WIRE) -- Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets.


Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electronics, SK Hynix, and Hyundai Motor offering meaningful exposure to some of Asia's most prominent and innovative industries. From a single unified platform, Interactive Brokers clients can seamlessly manage diversified global portfolios, trading stocks, options, futures, currencies, bonds, and funds across more than 170 markets worldwide, now including Korean equities through both the Korea Exchange and Nextrade.


"Korea is home to some of the world's most innovative companies, and its equity market has become increasingly central to global investment strategies," said David Friedland, Managing Director for Asia Pacific at Interactive Brokers. "By adding Nextrade alongside the Korea Exchange, we're giving clients greater flexibility and more ways to capture opportunities in one of Asia's most compelling markets, while further demonstrating our commitment to providing broad, cost-efficient market access worldwide."


Nextrade offers access to approximately 650 securities from the KOSPI and KOSDAQ markets, competitive fees, and an extended 12-hour trading window, running from 8:00 AM to 8:00 PM KST across three sessions. This expanded trading window gives clients greater flexibility to act on Korean market opportunities outside traditional exchange hours, whether responding to overnight global developments or coordinating trades across multiple time zones.


Nextrade operates from 8:00 AM to 8:00 PM KST across three sessions: Pre-Market (8:00-8:50 AM), Standard (9:00 AM-3:20 PM), and After-Market (3:30-8:00 PM).


For additional information visit:


US and countries served by IB LLC: Nextrade

Canada: Nextrade

United Kingdom: Nextrade

Europe: Nextrade

Hong Kong: Nextrade

Singapore: Nextrade

Australia: Nextrade

Japan: Nextrade


Access to equities on Nextrade through Interactive Brokers is not available to residents of Korea. Availability of products varies by Interactive Brokers affiliate and client country of residence.


The best-informed investors choose Interactive Brokers.


About Interactive Brokers Group, Inc.:

Interactive Brokers Group, Inc. (NASDAQ: IBKR) is a member of the S&P 500. Its affiliates provide automated trade execution and custody of securities, commodities, foreign exchange, and prediction markets around the clock on over 170 markets in numerous countries and currencies from a single unified platform to clients worldwide. We serve individual investors, hedge funds, proprietary trading groups, financial advisors and introducing brokers. Our four decades of focus on technology and automation have enabled us to equip our clients with a uniquely sophisticated platform to manage their investment portfolios. We strive to provide our clients with advantageous execution prices and trading, risk and portfolio management tools, research facilities and investment products, all at low or no cost, positioning them to achieve superior returns on investments. Interactive Brokers has consistently earned recognition as a top broker, garnering multiple awards and accolades from respected industry sources such as Barron's, Investopedia, Stockbrokers.com, and many others.


Follow Interactive Brokers on social media: Facebook, Instagram, LinkedIn, Reddit, X (Twitter), TikTok, YouTube


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260630285130/en/



Permalink

https://www.aetoswire.com/en/news/3006202656018


Contacts

Contacts for Interactive Brokers Group, Inc.

Media: Katherine Ewert, media@ibkr.com


 

Hytera Debuts SC700 Smart 4G Body Camera at CCW 2026


 LONDON - 

(BUSINESS WIRE) -- Hytera, a leading global provider of critical communications technologies and solutions, officially debuted its SC700 Smart 4G Body Camera at Critical Communications World (CCW) 2026.


Public safety operations are increasingly moving toward real-time, connected workflows, where communication, video, and situational awareness are integrated to support a faster and more coordinated response in the field. The SC700 is designed to support this shift. It enables live video, location sharing and push-to-talk communication, helping connect frontline officers with control rooms. Integrated with Hytera HyTalk PoC System, it also supports communication across broadband and PMR users to improve coordination across teams.


It also features Intelligent Scene Aware, which can detect abnormal situations such as man down, inactivity, or device tampering, and automatically alert dispatch centers.


“The role of body-worn camera is evolving beyond evidence capture,” said Leslie Li, Deputy General Manager of BWC Business Unit, Hytera. “It is becoming part of a connected operational workflow that links frontline personnel, control rooms, and decision-makers in real time.”


Designed for frontline use, the SC700 combines a long battery life, simple operation, and secure evidence handling, supporting organizations in improving situational awareness and operational response.


About Hytera


Hytera Communications Corporation Limited (SZSE: 002583) is a leading global provider of critical communications technologies and solutions. Hytera has been serving worldwide users over three decades with its innovative portfolio of two-way radios, PMRhttps://www.hytera.com/en/


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260630283236/en/



Permalink

https://aetoswire.com/en/news/3006202656007


Contacts

lele.yao@hytera.com

Tuesday, June 30, 2026

BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma


 SAN CARLOS, Calif. - 

Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p<0.0001), meeting the primary endpoint of PFS


MANGROVE is the first Phase 3 trial to advance a new chemotherapy-free standard in frontline MCL, potentially allowing patients freedom from the burden of years of infusions


Full results from MANGROVE, including efficacy and safety, will be presented at an upcoming medical meeting; global regulatory submissions are planned for 2H 2026


(BUSINESS WIRE) -- BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306; NCT04002297) evaluating foundational BTK inhibitor BRUKINSA® (zanubrutinib) plus rituximab versus bendamustine plus rituximab (BR) in adult patients with previously untreated mantle cell lymphoma (MCL). MANGROVE is the first Phase 3, global, randomized trial to evaluate a BTK inhibitor-based chemotherapy-free regimen against standard chemoimmunotherapy in this setting. This pivotal Phase 3 trial builds on the established clinical evidence for BRUKINSA in MCL.


Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said:

“For patients with newly diagnosed MCL, chemotherapy is currently the default. MANGROVE demonstrates for the first time that BRUKINSA plus rituximab, a chemotherapy-free regimen, can deliver unprecedented improvements in progression-free survival, potentially redefining the treatment paradigm globally. We believe it would be very meaningful for patients to be free from the burden of frequent infusions. This is what it means to state that BRUKINSA is foundational: another study where it anchors frontline therapy and extends its leadership across B-cell malignancies.”


Topline results with practice-changing potential


For this prespecified interim analysis, MANGROVE met its primary endpoint of progression-free survival (PFS), demonstrating a highly statistically significant and clinically meaningful improvement for BRUKINSA plus rituximab versus BR, as assessed by an independent review committee (IRC). This is the first Phase 3 study of its kind to employ a chemotherapy-free, rituximab maintenance-free approach in first-line MCL, sparing patients approximately two years of infusions. This BRUKINSA-based, chemotherapy-free regimen led to a 43% reduction in the risk of progression or death (HR=0.57; [95% CI, 0.43, 0.76]; p<0.0001). The safety profile of BRUKINSA plus rituximab was consistent with the known safety profile of both medicines, with no new safety signals identified. Overall survival (OS), a key secondary endpoint, was immature at the time of this analysis; however, a strong trend in favor of BRUKINSA plus rituximab was observed. OS will be tested as part of the final analysis.


Full results from MANGROVE will be shared at an upcoming medical meeting. The Company is in discussions with global regulatory authorities with planned submissions in 2H 2026.


Why a chemotherapy-free approach is needed in MCL


Mantle cell lymphoma is a rare and typically aggressive (fast-growing) type of B-cell non-Hodgkin lymphoma.1 It predominantly affects older adults, who often have comorbidities that can influence treatment decisions and how well they can tolerate therapies.2 Frontline care has long relied on chemoimmunotherapy such as BR.3


Chemoimmunotherapy carries well-documented burdens, including myelosuppression, prolonged immune suppression and heightened infection risk, and cumulative toxicity that can be especially difficult for older patients.4


Efforts to improve frontline outcomes in MCL with BTK inhibitors have largely focused on adding them to chemotherapy rather than replacing it.5 MANGROVE takes a different approach, by evaluating whether a chemotherapy-free regimen of BRUKINSA plus rituximab can deliver durable disease control while sparing patients the burden of upfront chemotherapy. This approach seeks to advance longstanding efficacy and tolerability limitations of first-line care.


About MANGROVE


MANGROVE is a global, randomized, open-label Phase 3 trial evaluating BRUKINSA plus rituximab versus bendamustine plus rituximab in adult patients with previously untreated mantle cell lymphoma. The trial enrolled 510 patients across 176 sites worldwide.


In the experimental arm, patients received BRUKINSA at 160 mg orally twice daily plus rituximab during the initial treatment period, followed by BRUKINSA monotherapy until disease progression or intolerance. In the control arm, patients received bendamustine plus rituximab for six cycles. The primary endpoint is PFS assessed by IRC. Overall survival is a key secondary endpoint for the study. Other secondary endpoints include investigator-assessed PFS, overall response rate (ORR), duration of response (DOR), patient-reported outcomes, and safety.


About BRUKINSA® (zanubrutinib)


BRUKINSA is a next-generation Bruton tyrosine kinase (BTK) inhibitor designed to deliver complete and sustained BTK inhibition, enabled by optimized pharmacokinetics, including bioavailability, half-life, and selectivity, resulting in consistent target coverage in disease-relevant tissues.


BRUKINSA is the foundational BTK inhibitor and the first and only to demonstrate progression-free survival superiority over another BTK inhibitor in a Phase 3 study, setting a new benchmark for efficacy in the class. With the broadest label globally, it is also the only BTK inhibitor that offers the convenience of once- or twice-daily dosing to support individualized treatment.


The global BRUKINSA clinical development program spans more than 8,000 patients across over 45 trials in 30+ countries and regions. Approved in more than 80 markets, BRUKINSA has been used to treat over 290,000 patients worldwide, reflecting its rapidly expanding role as a standard of care across B-cell malignancies.


Select Important Safety Information for BRUKINSA


Serious adverse reactions, including fatal events, have occurred with BRUKINSA, including hemorrhage, infections, cytopenias, second primary malignancies, cardiac arrhythmias, and hepatotoxicity (including drug-induced liver injury).


In the pooled safety population (N=1729), the most common adverse reactions (≥30%), including laboratory abnormalities, in patients who received BRUKINSA were neutrophil count decreased (51%), platelet count decreased (41%), upper respiratory tract infection (38%), hemorrhage (32%), and musculoskeletal pain (31%).


Please see full U.S. Prescribing Information including U.S. Patient Information.


About BeOne


BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before.


To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.


Forward-Looking Statement


This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the potential benefits of BRUKINSA plus rituximab as a chemotherapy-free regimen in adult patients with previously untreated MCL; the foundational potential of BRUKINSA to anchor frontline therapy on its own and extend its leadership across B-cell malignancies; the timing of clinical and regulatory developments and data readouts; and BeOne’s plans, commitments, aspirations, and goals under the heading “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.


To access BeOne media resources, please visit our Newsroom.


 


 

1 National Cancer Institute. Mantle cell lymphoma. NCI Dictionary of Cancer Terms. Accessed June 16, 2026. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/mantle-cell-lymphoma.


2 National Cancer Institute. Mantle Cell Lymphoma Treatment (PDQ®)–Health Professional Version. Accessed June 16, 2026.


3 Tix T, Kumar A, Eyre TA, Dreyling M. Modern management of mantle cell lymphoma. J Clin Oncol. 2026;46:e517468.


4 Blayney DW, Schwartzberg L. Chemotherapy‑induced neutropenia and emerging agents for prevention and treatment: a review. Cancer Treat Rev. 2022;109:102427.


5 Noor WD, Cheah CY. Recent advances and future directions in newly diagnosed mantle cell lymphoma. Expert Opin Pharmacother. 2025;26(13):1415-1432.


 


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260630413578/en/



Permalink

https://www.aetoswire.com/en/news/3006202656008


Contacts

Investor Contact

Liza Heapes

+1 857-302-5663

ir@beonemed.com


Media Contact

Kyle Blankenship

+1 667-351-5176

media@beonemed.com


 

Regnology Launches Regnology Risk Hub (RRiH) Ascend to Deliver Governed, AI Powered Intelligence to Balance Sheet and Enterprise Risk Management

 Powered by RGI, Regnology’s governed intelligence layer, the solution enables proactive, real-time decision-making across treasury, liquidity, and enterprise risk


(BUSINESS WIRE) -- Regnology, a global leading provider at the intersection of regulatory, risk, finance and supervisory technology, today announced the launch of Regnology Risk Hub (RRiH) Ascend, the next evolution of the Regnology Risk Hub (RRiH), now fully integrated into the Ascend platform.


Designed to help financial institutions move from reactive risk monitoring to proactive decision-making, RRiH Ascend leverages the combined expertise of the acquired OneSumX for Risk solution from Wolters Kluwer and Moody’s regulatory reporting & ALM solutions, bringing together comprehensive risk coverage, advanced analytics and governed intelligence in a single, cloud-native platform. The solution delivers integrated, enterprise-wide coverage across asset-liability management (ALM), liquidity management, market and credit risk, profitability, stress testing and prudential risk, providing consistent insight across business lines and legal entities, for both internal and regulatory reporting.


The launch introduces a suite of capabilities powered by RGI (Regnology’s governed intelligence layer), transforming risk data into contextual, action-ready intelligence. RGI Explain converts complex metrics into clear, role-specific insights and recommended next actions, while RGI Assist enables conversational interaction to generate scenarios, validate data and configure simulations, with embedded governance and human-validation checkpoints.


These AI capabilities are embedded across the risk lifecycle, letting users model market events and stress scenarios in minutes using natural language. RGI translates those inputs into structured simulations, applies relevant assumptions and stages outputs for review, accelerating decisions without compromising control.


“Financial institutions can no longer rely on fragmented data, siloed workflows or delayed analytics to manage their risk,” said Rob Mackay, CEO of Regnology. "RRiH Ascend transforms static reporting into continuous, governed intelligence, enabling firms to anticipate risk, act faster and make more informed strategic decisions."


RRiH Ascend is fully integrated with the broader Ascend ecosystem, bringing together data, analytics, governance and workflows through consistent design principles across risk, finance and regulatory domains. With real-time processing, end-to-end transparency and full audit-ready lineage, the solution supports Regnology’s vision of Straight-Through Reporting (STR), helping institutions reduce silos, improve data consistency and deliver an integrated view of risk.


"RRiH Ascend was designed to give every stakeholder, from analysts and risk managers to treasurers and CFOs, immediate access to the intelligence they need to make confident decisions," said Linda Middleditch, Chief Product Officer at Regnology. "By combining deep risk expertise with purpose-built workflows and contextual AI, we are enabling institutions to move beyond mere compliance toward a future where risk management becomes a proactive, strategic function," added Shan Goyal, Product Director at Regnology.


Regnology will continue to evolve RRiH Ascend with agentic AI, advanced analytics and cloud-native scalability keeping the platform at the forefront of risk innovation.


About Regnology


Regnology is a recognized leader in regulatory, risk, tax, and finance reporting technology— connecting regulators and the regulated across more than 100 countries. Our unique position enables us to span the full spectrum of industry needs, delivering solutions that address both oversight and compliance requirements to a broad range of clients, including global Tier 1 banks, local and regional institutions, corporates, insurers, and authorities.


For more information about Regnology, connect with us on LinkedIn and X.


Visit our website: www.regnology.net.


https://www.regnology.net/en/resources/news/regnology-risk-hub-ascend-delivers-ai-intelligence-to-balance-sheet-and-enterprise-risk/?utm_campaign=2026-06-risk-ascend-hub&utm_source=businesswire&utm_medium=pr


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260629063140/en/



Permalink

https://aetoswire.com/en/news/3006202656004


Contacts

Mireille Adebiyi – Chief Marketing Officer

Email: mireille.adebiyi@regnology.net